Lorbrexen (Lorlatinib) 100 MG – 30 Tablets
Price: $400.00
Lorbrexen 100 mg (Lorlatinib) is a potent, brain-penetrant, third-generation inhibitor of ALK and ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity was seen in patients with ALK-positive non-small-cell lung cancer, most of whom had CNS metastases and progression after ALK-directed therapy.
100 mg PO qDay with or without food
Continue until disease progression or unacceptable toxicity.
Description
Product Features:
| Product Name | : Lorbrexen |
| Generic Name | : Lorlatinib |
| Manufacturer | : Everest Pharma Ltd |
| Indication | : Non small cell lung cancer |
| Formulation | : Tablet |
| Strength | : 100 mg |
| Quantity | : 30 Tablets |
| Storage | : Below 25°C |
| Registrations | : Export Only |
Lorbrexen 100 mg (Lorlatinib), generic Lorbrena is a prescription medicine. It is used to treat metastatic non-small cell lung cancer in patients who have a certain type of abnormal anaplastic lymphoma kinase (ALK) gene. These uses in patients who have already received alectinib, ceritinib or both crizotinib. At least 1 other medicine to treat NSCLC that is caused by the ALK gene.
Recommended Dosage
The recommended dosage of LORBRENA is 100 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
Swallow tablets whole and chew, crush or split tablets. Do not ingest broken tablets, cracked, or otherwise not intact.
Take Lorbrexen at the same time each day. One dose is missed, then take the missed dose. Unless the next dose is due within 4 hours. Please not take 2 doses at the same time to make up for a missed dose.
Do not take an additional dose if vomiting occurs after Lorbrexen but continue with the next scheduled dose.
Lorlatinib Dosage Modifications for Adverse Reactions
The recommended dose reductions are:
First dose reduction: Lorbrexen 100 mg orally once daily. Second dose reduction: LORBRENA 50 mg orally once daily
Disease interactions Lorlatinib 100 mg
There are 8 disease interactions with Lorbrexen which include:
- Interstitial lung disease
- Atrioventricular block
- CNS effects
- Hepatotoxicity/hepatic impairment
- Hyperglycemia
- Hyperlipidemia
- Hypertension
- Severe renal impairment
For Healthcare Professionals
Applies to lorlatinib: Oral tablet
Hematologic
Very common (10% or more): Anemia (52%), thrombocytopenia (23%), lymphopenia (22%).
Musculoskeletal
Very common (10% or more): Arthralgia (23%), myalgia/musculoskeletal pain (17%), back pain (13%), pain in extremity (13%).
Ocular
Very common (10% or more): Vision disorder (e.g., diplopia, photophobia, photopsia, vision blurred, visual acuity reduced, visual impairment, vitreous floaters) (15%).
Metabolic
Most common (10% or more): Hypercholesterolemia (96%), hypertriglyceridemia (90%), edema (edema peripheral, eyelid edema, face edema, generalized edema, localized edema, periorbital edema, peripheral swelling, swelling) (57%), hyperglycemia (52%), hypoalbuminemia (33%), weight gain (24%), increased lipase (24%), increased alkaline phosphatase (24%), increased amylase (22%), hypophosphatemia (21%), hyperkalemia (21%), hypomagnesemia (21%), Grade 3 or 4 elevations in total cholesterol 17%), Grade 3 or 4 elevations in triglycerides (17%).
Psychiatric
Common (10% or more): Cognitive effects (e.g., amnesia, cognitive disorder, dementia, disturbance in attention, memory impairment, mental impairment, attention deficit/hyperactivity disorder, confusional state, delirium, disorientation, reading disorder) (29%), changes in mood (24%), changes in sleep (e.g., abnormal dreams, insomnia, nightmare, sleep disorder, sleep talking, somnambulism) (10%).
Common (1% to 10%): Hallucinations, mental status changes, (10%).
Hepatic
Very common (10% or more): Grade 4 ALT/AST elevation when taken concomitantly with a strong CYP450 3A inducer (50%), Grade 3 ALT/AST elevation when taken concomitantly with a strong CYP450 3A inducer (33%)
Common (1% to 10%): Grade 2 ALT/AST elevation when taken concomitantly with a strong CYP450 3A inducer
Respiratory
Very common (10% or more): Dyspnea (27%), cough (18%), upper respiratory tract infection (e.g., fungal upper respiratory infection, viral upper respiratory infection) (12%).
Common (1% to 10%): Interstitial lung disease (ILD), pneumonitis.
For more Oncology medicine, visit our SHOP
Related products
-
Lorbrexen (Lorlatinib) 100 MG – 30 Tablets
Price: $400.00
Reviews
There are no reviews yet.